Teleflex (BSP:T1FX34) Common Stock : R$239 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Teleflex Common Stock?

Teleflex's quarterly common stock declined from Sep. 2023 (R$237 Mil) to Dec. 2023 (R$235 Mil) but then increased from Dec. 2023 (R$235 Mil) to Mar. 2024 (R$239 Mil).

Teleflex's annual common stock declined from Dec. 2021 (R$271 Mil) to Dec. 2022 (R$252 Mil) and declined from Dec. 2022 (R$252 Mil) to Dec. 2023 (R$235 Mil).

Teleflex Common Stock Historical Data

The historical data trend for Teleflex's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teleflex Common Stock Chart

Teleflex Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

195.11

245.98

271.03

251.55

235.42

Teleflex Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															249.88	232.97	237.05	235.42	239.43

Teleflex Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Teleflex (BSP:T1FX34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Teleflex Inc (BSP:T1FX34) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

TFX:USA

Address

550 East Swedesford Road, Suite 400, Wayne, PA, USA, 19087

Website

https://www.teleflex.com

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2022 sales), interventional (16%), anesthesia (14%), surgical (14%), interventional urology (12%), original-equipment manufacturing (10%), and all other (10%). Geographic exposure for the business is primarily in the U.S., which accounts for 60% of revenue, with international markets making up the remainder.

Teleflex (BSP:T1FX34) Headlines

No Headlines